

CITATION REPORT

List of articles citing

Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor

DOI: 10.1073/pnas.0510187103

Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 8634-9.

Source: <https://exaly.com/paper-pdf/41105299/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
146	Apoptosis in the treatment of cancer: a promise kept?. 2006 , 18, 668-76		59
145	Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. 2007 , 6, 3219-28		25
144	Death receptor-mediated liver injury. 2007 , 27, 327-38		52
143	Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. 2007 , 13, 4556-64		56
142	Screening of a novel octamer peptide, CNSCWSKD, that induces caspase-dependent cell death. <i>Biochemical and Biophysical Research Communications</i> , 2007 , 362, 1063-8	3.4	24
141	The stability effects of protein mutations appear to be universally distributed. 2007 , 369, 1318-32		295
140	Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. 2007 , 282, 28189-94		55
139	TRAIL in cancer therapy: present and future challenges. 2007 , 11, 1299-314		124
138	Survey of the year 2006 commercial optical biosensor literature. 2007 , 20, 300-66		94
137	Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide. 2007 , 67, 1194-201		7
136	Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. 2007 , 25, 786-93		444
135	Structures in systems biology. 2007 , 17, 378-84		53
134	Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells. 2008 , 86, 909-24		25
133	RGD-avidin-biotin pretargeting to alpha v beta 3 integrin enhances the proapoptotic activity of TNF alpha related apoptosis inducing ligand (TRAIL). 2008 , 13, 225-35		10
132	Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. <i>Oncogene</i> , 2008 , 27, 3211-20	9.2	84
131	The TRAIL apoptotic pathway in cancer onset, progression and therapy. 2008 , 8, 782-98		690
130	Computational design of protein therapeutics. 2008 , 5, e43-8		23

129	TRAIL and cancer therapy. <i>Cancer Letters</i> , 2008 , 263, 14-25	9.9	140
128	Analyzing protein interaction networks using structural information. 2008 , 77, 415-41		71
127	DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. 2008 , 283, 20560-8		46
126	Genome-wide prediction of SH2 domain targets using structural information and the FoldX algorithm. 2008 , 4, e1000052		35
125	The Impact of Structural Proteomics on the Prediction of Protein-Protein Interactions. 2008 , 251-267		
124	Therapeutic targeting of apoptosis pathways in cancer. 2008 , 20, 97-103		66
123	The TRAIL to targeted therapy of breast cancer. 2009 , 103, 43-73		60
122	Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. 2009 , 15, 2048-57		43
121	Stem cells are resistant to TRAIL receptor-mediated apoptosis. 2009 , 13, 4409-14		38
120	"APRIL hath put a spring of youth in everything": Relevance of APRIL for survival. 2009 , 218, 1-8		21
119	Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5. 2009 , 14, 778-87		34
118	In vivo folding efficiencies for mutants of the P22 tailspike beta-helix protein correlate with predicted stability changes. 2009 , 141, 186-92		6
117	TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. 2009 , 113, 217-30		138
116	Quantitative structure activity relationship of IA3-like peptides as aspartic proteinase inhibitors. 2009 , 75, 859-69		8
115	Design of protein-interaction specificity gives selective bZIP-binding peptides. 2009 , 458, 859-64		287
114	Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways. <i>FEBS Journal</i> , 2009 , 276, 6912-27 ⁵⁻⁷		17
113	TRAIL receptor signalling and modulation: Are we on the right TRAIL?. 2009 , 35, 280-8		227
112	Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. 2009 , 136, 2365-2376.e1-7		59

111	Death Receptors at the Molecular Level: Therapeutic Implications. 2009 ,		
110	Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. 2009 , 48, 2180-91		27
109	Protein design in biological networks: from manipulating the input to modifying the output. 2009 , 22, 537-42		22
108	A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. 2009 , 8, 2276-85		24
107	Modulating Protein Interactions By Rational And Computational Design. 2009 ,		
106	?????????????????????????????????????. 2009 , 47, 630-637		
105	Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. 2010 , 15, 1256-69		29
104	Evolution: a guide to perturb protein function and networks. 2010 , 20, 351-9		22
103	Optimization algorithms for functional deimmunization of therapeutic proteins. 2010 , 11, 180		40
102	Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. 2010 , 1805, 123-40		82
101	Synthetic constrained peptide selectively binds and antagonizes death receptor 5. <i>FEBS Journal</i> , 2010 , 277, 1653-65	5-7	15
100	Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells. 2010 , 102, 754-64		30
99	Inhibition of IGF-1R-Dependent PI3K Activation Sensitizes Colon Cancer Cells Specifically to DR5-Mediated Apoptosis But Not to rhTRAIL. 2010 , 33, 229-244		3
98	Capturing, sharing and analysing biophysical data from protein engineering and protein characterization studies. 2010 , 38, e186		5
97	Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. 2010 , 9, 1719-29		61
96	Fusicoccin-A selectively induces apoptosis in tumor cells after interferon-alpha priming. <i>Cancer Letters</i> , 2010 , 293, 198-206	9-9	43
95	TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. 2010 , 13, 2-15		62
94	Engineering signal transduction pathways. 2010 , 140, 33-47		94

93	TRAIL: a sword for killing tumors. 2010 , 17, 3309-17	29
92	Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy. 2010 , 10, 1-18	42
91	Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. 2010 , 1, e83	55
90	Advances in TNF Family Research. <i>Advances in Experimental Medicine and Biology</i> , 2011 ,	3.6 3
89	Novel transcript variants of TRAIL show different activities in activation of NF- κ B and apoptosis. 2011 , 89, 839-46	8
88	Unraveling the binding mechanism of trivalent tumor necrosis factor ligands and their receptors. 2011 , 10, M110.002808	21
87	Targeting TRAIL towards the clinic. 2011 , 12, 2079-90	20
86	Targeting AML through DR4 with a novel variant of rhTRAIL. 2011 , 15, 2216-31	17
85	Computational design of peptide ligands. 2011 , 29, 231-9	111
84	Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL. 2011 , 34, 245-59	4
83	Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. 2011 , 11, 39	27
82	Combination of IFN γ and chemotherapeutic agents increase TRAIL sensitivity of neuroblastoma cell lines. 2011 , 21, 304-9	4
81	The molecular machinery regulating apoptosis signal transduction and its implication in human physiology and pathophysiology. 2011 , 11, 31-47	40
80	Therapeutic targeting of CD95 and the TRAIL death receptors. 2011 , 6, 294-310	18
79	Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL. 2012 , 11, M111.013730	23
78	Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer. 2012 , 12, 170-84	51
77	The design and characterization of receptor-selective APRIL variants. 2012 , 287, 37434-46	8
76	Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. 2012 , 72, 4562-73	50

75	Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. 2012 , 3, e295		47
74	Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. 2012 , 7, e45492		12
73	Designing specific protein-protein interactions using computation, experimental library screening, or integrated methods. 2012 , 21, 949-63		37
72	Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells. 2012 , 125, 4651-61		52
71	A novel classification system to predict the pathogenic effects of CHD7 missense variants in CHARGE syndrome. 2012 , 33, 1251-60		52
70	TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. 2012 , 11, 3-13		113
69	Antibody-free LC-MS/MS quantification of rhTRAIL in human and mouse serum. 2013 , 85, 10754-60		21
68	Engineering death receptor ligands for cancer therapy. <i>Cancer Letters</i> , 2013 , 332, 163-74	9.9	52
67	Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. 2013 , 57, 625-36		42
66	Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects. 2013 , 4, e503		38
65	Translating TRAIL-receptor targeting agents to the clinic. <i>Cancer Letters</i> , 2013 , 332, 194-201	9.9	61
64	Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. <i>Cell Death and Differentiation</i> , 2013 , 20, 858-68	12.7	126
63	Identification of somatic mutations in human prostate cancer by RNA-Seq. 2013 , 519, 343-7		19
62	Death receptors as targets in cancer. 2013 , 169, 1723-44		135
61	Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. 2013 , 109, 2685-95		29
60	Structure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactions. 2013 , 9, e1003224		32
59	Comprehensive analysis of surface charged residues involved in thermal stability in Alicyclobacillus acidocaldarius esterase 2. 2013 , 26, 47-58		16
58	Real-time detection of cellular death receptor-4 activation by fluorescence resonance energy transfer. 2013 , 110, 1396-404		3

57	Improving the anti-toxin abilities of the CMG2-Fc fusion protein with the aid of computational design. 2014 , 9, e104674		3
56	DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer. 2014 , 15, 1658-66		26
55	Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment. 2014 , 289, 1071-8		13
54	Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function?. 2014 , 91, 447-56		45
53	The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma. 2014 , 3, 495		12
52	Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells. <i>Frontiers in Oncology</i> , 2015 , 5, 69	5-3	150
51	Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells. 2015 , 39, 657-66		36
50	Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells. 2015 , 80, 1080-91		6
49	Therapeutic applications of TRAIL receptor agonists in cancer and beyond. 2015 , 155, 117-31		53
48	TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill. 2015 , 15, 494		17
47	The Janus Face of Death Receptor Signaling during Tumor Immunoediting. 2016 , 7, 446		25
46	Protein engineering strategies with potential applications for altering clinically relevant cellular pathways at the protein level. <i>Expert Review of Proteomics</i> , 2016 , 13, 481-93	4-2	2
45	High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer. <i>Cancer Letters</i> , 2016 , 383, 250-260	9-9	33
44	Highly sensitive antibody-free LC-MS/MS quantification of rhTRAIL in serum. <i>Bioanalysis</i> , 2016 , 8, 881-902.1		9
43	The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL-induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells. <i>International Journal of Oncology</i> , 2016 , 49, 74-88	4-4	21
42	Onto better TRAILs for cancer treatment. <i>Cell Death and Differentiation</i> , 2016 , 23, 733-47	12-7	201
41	Preparation and characterization of a novel variant of human tumor necrosis factor-related apoptosis-inducing ligand from the rhesus monkey, <i>Macaca mulatta</i> . <i>Applied Microbiology and Biotechnology</i> , 2016 , 100, 3035-47	5-7	6
40	Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. <i>Oncogene</i> , 2016 , 35, 1261-70	9-2	45

39	CD25 targeted therapy of chemotherapy resistant leukemic stem cells using DR5 specific TRAIL peptide. <i>Stem Cell Research</i> , 2017 , 19, 65-75	1.6	7
38	TRAIL-death receptor endocytosis and apoptosis are selectively regulated by dynamin-1 activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 504-509	11.5	36
37	Fn14-TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog. <i>Cancer Letters</i> , 2017 , 400, 99-109	9.9	10
36	Achievements and Challenges in Computational Protein Design. <i>Methods in Molecular Biology</i> , 2017 , 1529, 21-94	1.4	8
35	Novel RANKL DE-loop mutants antagonize RANK-mediated osteoclastogenesis. <i>FEBS Journal</i> , 2017 , 284, 2501-2512	5.7	8
34	TRAIL-NP hybrids for cancer therapy: a review. <i>Nanoscale</i> , 2017 , 9, 5755-5768	7.7	29
33	Receptor-specific TRAIL as a means to achieve targeted elimination of activated hepatic stellate cells. <i>Journal of Drug Targeting</i> , 2017 , 25, 360-369	5.4	10
32	TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2018 , 1865, 522-531	4.9	11
31	Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment. <i>Journal of Immunology</i> , 2018 , 200, 1110-1123	5.3	7
30	Generation of rationally-designed nerve growth factor (NGF) variants with receptor specificity. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 495, 700-705	3.4	7
29	TNF-family member Receptor Activator of NF- κ B (RANK) and RANK-Ligand (RANKL) in bone remodelling. <i>IOP Conference Series: Earth and Environmental Science</i> , 2018 , 185, 012001	0.3	
28	A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 829-838	3.5	6
27	Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists. <i>Cancers</i> , 2019 , 11,	6.6	14
26	Creation of RANKL mutants with low affinity for decoy receptor OPG and their potential anti-fibrosis activity. <i>FEBS Journal</i> , 2019 , 286, 3582-3593	5.7	4
25	Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells. <i>Cancers</i> , 2019 , 11,	6.6	23
24	Hsp90 Inhibitor SNX-2112 Enhances TRAIL-Induced Apoptosis of Human Cervical Cancer Cells via the ROS-Mediated JNK-p53-Autophagy-DR5 Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2019 , 2019, 9675450	6.7	13
23	Death receptor 5 is activated by fucosylation in colon cancer cells. <i>FEBS Journal</i> , 2019 , 286, 555-571	5.7	14
22	Elucidation for modulation of death receptor (DR) 5 to strengthen apoptotic signals in cancer cells. <i>Archives of Pharmacal Research</i> , 2019 , 42, 88-100	6.1	14

21	Artemisinin Derivatives Stimulate DR5-Specific TRAIL-Induced Apoptosis by Regulating Wildtype P53. <i>Cancers</i> , 2020 , 12,	6.6	7
20	Death Receptor 5 Displayed on Extracellular Vesicles Decreases TRAIL Sensitivity of Colon Cancer Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 318	5.7	8
19	Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile. <i>Translational Oncology</i> , 2020 , 13, 100762	4.9	1
18	Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant. <i>HemaSphere</i> , 2021 , 5, e561	0.3	7
17	Engineering Exosomes Endowed with Targeted Delivery of Triptolide for Malignant Melanoma Therapy. <i>ACS Applied Materials & Interfaces</i> , 2021 , 13, 42411-42428	9.5	8
16	Computational design of TNF ligand-based protein therapeutics. <i>Advances in Experimental Medicine and Biology</i> , 2011 , 691, 521-34	3.6	1
15	Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017 , 107-129	0.3	1
14	Apoptosis Modulators: p53 Targeting. 2007 , 189-208		1
13	Generation of Tumour-stroma Minispheroids for Drug Efficacy Testing. <i>Bio-protocol</i> , 2017 , 7, e2091	0.9	
12	TRAIL and TRAIL Receptors as Prognostic Markers in Breast Cancer Patients. <i>American Journal of Molecular Biology</i> , 2019 , 09, 204-217	0.2	
11	Insilico investigation of TNFSF10 signaling cascade in ovarian serous cystadenocarcinoma. 2019 , 3, 025-034		
10	Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist. <i>Cancer Letters</i> , 2022 , 525, 67-75	9.9	2
9	Targeted ovarian cancer treatment: the TRAILs of resistance. <i>American Journal of Cancer Research</i> , 2012 , 2, 75-92	4.4	25
8	Macrophage-like THP-1 Cells Derived from High-Density Cell Culture Are Resistant to TRAIL-Induced Cell Death via Down-Regulation of Death-Receptors DR4 and DR5.. <i>Biomolecules</i> , 2022 , 12,	5.9	1
7	Dihydroartemisinin-Transferrin Adducts Enhance TRAIL-Induced Apoptosis in Triple-Negative Breast Cancer in a P53-Independent and ROS-Dependent Manner.. <i>Frontiers in Oncology</i> , 2021 , 11, 789336	5.3	2
6	Receptor Specificity Engineering of TNF Superfamily Ligands.. <i>Pharmaceutics</i> , 2022 , 14,	6.4	2
5	A High Throughput Approach for Designing Polymers That Mimic the TRAIL Protein.. <i>Nano Letters</i> , 2022 ,	11.5	2
4	Natural killer cell-mimic nanoparticles can actively target and kill acute myeloid leukemia cells.		0

- 3 DR5 Up-Regulation Induced by Dichloroacetate Sensitizes Tumor Cells to Lipid Nanoparticles Decorated with TRAIL. **2023**, 12, 608
- 2 Natural killer cell-mimic nanoparticles can actively target and kill acute myeloid leukemia cells. **2023**, 122126
- 1 Nanoparticle drug delivery systems for synergistic delivery of tumor therapy. 14,